Impact of PCSK9 Immunization on Glycemic Indices in Diabetic Rats by Amir Abbas Momtazi-Borojeni, Mahmoud Reza Jaafari, Elham Abdollahi, Maciej Banach, Amirhossein Sahebkar

“…The impact of Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition on glycemic indices in diabetes mellitus remains far from clear. …”
Get full text

New epigenome players in the regulation of PCSK9-H3K4me3 and H3K9ac alterations by statin in hypercholesterolemia by Sushmitha Duddu, Yash T. Katakia, Rituparna Chakrabarti, Pooja Sharma, Praphulla Chandra Shukla

“…Despite its prevalent use, statins are known to increase proprotein convertase subtilisin/kexin type 9 (PCSK9) expression, hindering its efficiency. …”
Get full text

Serum PCSK9 Correlates with PTX3 and Apolipoproteins B, A1, and C3 Concentrations in Patients with Type 2 Diabetes by Małgorzata Waluś-Miarka, Maria Kapusta, Przemysław Miarka, Ewa Kawalec, Barbara Idzior-Waluś

“…Proprotein convertase subtilisin/kexin type 9 (PCSK9) is involved in the regulation of LDL metabolism. …”
Get full text

Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of coronary heart disease: a study protocol for a randomized controll... by Xing Gong, Xinting Yu, Lanlan Pu, Yang Jiao, Lin Liu, Hua Cao, Xiaofei Ji

“…Shared risk factors between CHD and AIS, especially elevated low-density lipoprotein cholesterol (LDL-C), contribute to atherosclerosis and inflammation, which worsen brain tissue damage. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors offer a promising treatment option. …”
Get full text

Apolipoproteins A and B and PCSK9: Nontraditional Cardiovascular Risk Factors in Chronic Kidney Disease and in End-Stage Renal Disease by Cristiana-Elena Vlad, Liliana Foia, Roxana Popescu, Iuliu Ivanov, Mihaela Catalina Luca, Carmen Delianu, Vasilica Toma, Cristian Statescu, Ciprian Rezus, Laura Florea

“…Nontraditional cardiovascular risk factors as apolipoprotein A (ApoA), apolipoprotein B (ApoB), and the proprotein convertase subtilisin/kexin type 9 (PCSK9) increase the prevalence of cardiovascular mortality in chronic kidney disease (CKD) or in end-stage renal disease (ESRD) through quantitative alterations. …”
Get full text

Effect of PCSK9 Inhibitor on Blood Lipid Levels in Patients with High and Very-High CVD Risk: A Systematic Review and Meta-Analysis by Yue Zhang, Yanrong Suo, Lin Yang, Xiaolu Zhang, Qun Yu, Miao Zeng, Wenlan Zhang, Xijuan Jiang, Yijing Wang

“…We aimed to investigate the effects of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor on blood lipid levels in patients with high and very-high cardiovascular risk. …”
Get full text

Mutual mediation effects of homocysteine and PCSK9 on coronary lesion severity in patients with acute coronary syndrome: interplay with inflammatory and lipid markers by Ping Jin, Juan Ma, Peng Wu, Yitong Bian, Xueping Ma, Shaobin Jia, Qiangsun Zheng

“…Abstract Background Homocysteine (Hcy) and the proprotein convertase subtilisin/kexin type 9 (PCSK9) significantly contribute to atherosclerosis (AS) as well as coronary lesion severity. …”
Get full text

The relationship between oxLDL, sLOX-1, PCSK9 and carotid intima-media thickness in patients with prediabetes and type 2 diabetes by Zeki Dogan, Abdulhalim Senyigit, Sinem Durmus, Canan Duvarcı, Remise Gelişgen, Hafize Uzun, Omur Tabak

“…The aim of this study was to evaluate the relationship between circulating oxidized LDL (oxLDL), soluble lectin-like oxidized LDL (sLOX)-1 and proprotein convertase subtilisin/kexin type 9 (PCSK9) levels and carotid intima-media thickness (CIMT) in patients with prediabetes and T2DM. …”
Get full text

Evolocumab safety and efficacy in hypercholesteremia patients with or without diabetes: a retrospective real-world analysis by Sultan Ibrahim Alraddadi, Hind Almodaimegh, Abdullah Kharbosh, Hadeel Alharbi, Ahmed Ibrahim Fathelrahman, Mona Yaser Alsheikh, Lama Alfehaid

“…Abstract Background Proprotein convertase subtilisin/kexin type 9 inhibitors effectively reduce LDL cholesterol and adverse cardiovascular events with a safety profile comparable to a placebo. …”
Get full text

PCSK9-antibodies fail to block PCSK9-induced inflammation in macrophages and cannot recapitulate protective effects of PCSK9-deficiency in experimental myocardial infarction by Simon Rauterberg, Simon Rauterberg, Carmen Härdtner, Jennifer Hein, Paola Schrepf, Remi Peyronnet, Christoph Koentges, Tamara A. Vico, Carolin Ehlert, Bianca Dufner, Diana Lindner, Constantin von zur Mühlen, Dennis Wolf, Dirk Westermann, Ingo Hilgendorf, Alexander von Ehr

“…Background and aimsProprotein convertase subtilisin/kexin type 9 (PCSK9) plays a crucial role in cholesterol homeostasis by regulating low-density lipoprotein (LDL) receptor levels. …”
Get full text

Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein cholesterol in hyperlipidemia patients: a systematic network me... by Yuhua Jiang, Yingying Wang, Sijia Ma, Linlin Qian, Yeteng Jing, Xi Chen, Jinsheng Yang

“…BackgroundThe objective of this study is to assess the relative efficacy of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, such as alirocumab, evolocumab, and inclisiran, in conjunction with potent statins like atorvastatin and rosuvastatin, in patients presenting with hyperlipidemia or heightened cardiovascular risk attributable to elevated low-density lipoprotein cholesterol (LDL-C).MethodsA systematic search was conducted across databases including PubMed, Embase, and the Cochrane Library to explore lipid-lowering therapies in hyperlipidemia from their inception to 7 November 2023. …”
Get full text

Aerobic exercise alleviates statin-induced PCSK9 upregulation by increasing epoxyeicosatrienoic acid levels through the FoxO3a–Sirt6 axis by Jiahui Hu, Hao Lei, Jingyuan Chen, Leiling Liu, Yajun Gui, Kaijun Sun, Danyan Xu

“…Background: Statins are the cornerstone of low-density lipoprotein cholesterol (LDL-C)-lowering therapy; however, the therapeutic efficacy of statins in countering atherosclerotic cardiovascular disease (ASCVD) is compromised by the concurrent elevation of proprotein convertase subtilisin/kexin type 9 (PCSK9), a pivotal molecule that increases LDL-C levels. …”
Get full text

Targeting PCSK9, through an innovative cVLP-based vaccine, enhanced the therapeutic activity of a cVLP-HER2 vaccine in a preclinical model of HER2-positive mammary carcinoma by Laura Scalambra, Francesca Ruzzi, Olga Maria Pittino, Maria Sofia Semprini, Chiara Cappello, Stefania Angelicola, Arianna Palladini, Patrizia Nanni, Louise Goksøyr, Cyrielle Fougeroux, Manuel L. Penichet, Adam Frederik Sander, Pier-Luigi Lollini

“…However, resistance and incomplete response remain considerable challenges. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition is a novel therapeutic strategy for the management of dyslipidemia by enhancing the clearance of low-density lipoprotein cholesterol receptors, however recent evidence also shows links between PCSK9 and cancer cells. …”
Get full text